Thrombophylaxis in Transurethral Surgery With Dalteparine
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The rationale for thrombophrophylaxis is well known. Without prophylaxis the incidence of
objectivlely confirmed, hospital-acquired deep venous thrombosis is approximately 10% to 40%
among medical or general surgical patients. In urology the prevalence is 15-40%. The Seventh
ACCP Conference on Antithrombotic and Thrombolytic Therapy1 recommend against specific
prophylaxis in patients undergoing transurethral procedures. Our study is the first
double-blind, placebo-controlled study with Dalteparine as thrombophrophylaxis in
transurethral surgery. The aim of the study is to proof that thrombophrophylaxis causes not
more complications in transurethral surgery than without.